Valuation: Verastem, Inc.

Market Cap 55Cr 48Cr 45Cr 41Cr 77Cr 5.24TCr 79Cr 532.45Cr 208.23Cr 2.59TCr 205.54Cr 201.08Cr 8.97TCr P/E 2026 *
-3.93x
P/E 2027 * -5.56x
Enterprise Value 38Cr 34Cr 31Cr 29Cr 54Cr 3.66TCr 55Cr 371.97Cr 145.47Cr 1.81TCr 143.59Cr 140.47Cr 6.27TCr EV / Sales 2026 *
3.75x
EV / Sales 2027 * 1.89x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-1.20%
1 week+3.74%
Current month+59.95%
1 month+59.95%
3 months+13.15%
6 months-4.68%
Current year-20.85%
1 week 5.75
Extreme 5.75
6.46
1 month 3.74
Extreme 3.745
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
22/06/26 Sell

Chief Executive Officer

-20,871 0.0339%
22/06/26 Sell

Chief Financial Officer

-4,089 0.0066%
21/05/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+3.74%-2.86%-44.76% 55Cr
+0.47%+2.27%+50.78%+69.72% 5.5TCr
+2.83%+0.04%+38.07%+82.59% 5.42TCr
+1.93%+1.60%-16.31%-14.30% 2.34TCr
+0.44%-2.42%-0.90%+371.07% 2.26TCr
+2.07%+1.44%+23.06%-9.05% 2.02TCr
-2.15%-2.30%+27.27%-33.01% 1.79TCr
-2.14%-2.72%+30.26%+536.72% 1.55TCr
-3.14%-8.09%+160.68%+292.18% 1.42TCr
-0.80%+1.90%+51.66%+184.25% 1.42TCr
Average -0.18%+0.07%+36.17%+143.54% 2.38TCr
Weighted average by Cap. +0.60%-0.19%+37.41%+128.92%

Financials

2026 *2027 *
Net sales 10Cr 8.95Cr 8.36Cr 7.67Cr 14Cr 975.76Cr 15Cr 99Cr 39Cr 482.85Cr 38Cr 37Cr 1.67TCr 18Cr 16Cr 15Cr 13Cr 25Cr 1.71TCr 26Cr 173.46Cr 68Cr 845.33Cr 67Cr 66Cr 2.92TCr
Net income -17Cr -15Cr -14Cr -12Cr -23Cr -1.59TCr -24Cr -160.99Cr -63Cr -784.55Cr -62Cr -61Cr -2.71TCr -14Cr -12Cr -12Cr -11Cr -20Cr -1.36TCr -21Cr -138.17Cr -54Cr -673.35Cr -53Cr -52Cr -2.33TCr
Net Debt -16Cr -14Cr -14Cr -12Cr -23Cr -1.58TCr -24Cr -160.48Cr -63Cr -782.06Cr -62Cr -61Cr -2.7TCr -21Cr -18Cr -17Cr -16Cr -30Cr -2.01TCr -30Cr -203.86Cr -80Cr -993.46Cr -79Cr -77Cr -3.43TCr
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
30/26/30 $6.125 -1.69% 12,26,217
28/26/28 $6.230 +2.47% 12,75,019
27/26/27 $6.080 +0.50% 22,44,215
24/26/24 $6.050 -2.10% 25,31,721
23/26/23 $6.180 +4.92% 21,93,680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.230USD
Average target price
15.00USD
Spread / Average Target
+140.77%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock